Last medical review: February 2026 · Read time: 6 min
Important notice: Pulmonary fibrosis is a complex condition. Cell therapy seeks to stabilize the disease and improve quality of life, but it does not completely reverse already scarred tissue. It is a complementary treatment to standard pneumological management.
Pulmonary Fibrosis (PF) behaves like a "silent scar" that advances relentlessly. Healthy, elastic lung tissue is progressively replaced by fibrous (hard) tissue, hindering oxygen exchange. For the patient, this means a daily struggle to breathe and an increasing dependence on supplemental oxygen.
Until recently, the outlook was bleak: anti-fibrotic drugs that only slow the process or the uncertain wait for a lung transplant. However, recent research published in 2025 has focused on the ability of regenerative medicine to attack the root of the problem: uncontrolled inflammation in respiratory organs and tissues.
How Do Stem Cells Act in the Lung?
Unlike chemical drugs, Mesenchymal Stem Cells (MSCs) act as "living medicines." When introduced into the body (usually intravenously), they are temporarily trapped in the pulmonary filter (an effect known as the "pulmonary first pass"), which is a strategic advantage in this disease.
Their mechanisms of action include:
- Anti-fibrotic Effect: They send signals to inhibit fibroblasts, the cells responsible for creating hard scar tissue.
- Potent Immunomodulation: They regulate the immune system response, reducing the chronic inflammation that fuels fibrosis.
- Angiogenesis: They promote the formation of new micro-blood vessels, improving oxygenation of the remaining tissue.
Recent Scientific Evidence (2025 Study)
A systematic review recently published in The FASEB Journal (January 2025) analyzed 13 clinical studies conducted between 2013 and 2021, covering almost 200 patients. The findings are hopeful for those seeking options:
The analysis concluded that cell therapy demonstrated a solid safety profile (no serious adverse events). Clinically, distinct levels of improvement were observed in forced vital capacity (FVC) and in the 6-minute walk distance, both in patients with mild disease and in those with rapid progression. The authors' conclusion is clear: stem cells are emerging as a "beacon of hope" to stabilize respiratory function.
Critical Safety: Why the Laboratory Matters
Treating the lungs requires absolute purity. Injecting cells that have not been processed under strict standards can cause micro-embolisms or infections.
At Regencord, we guarantee patient safety through:
- ISO 14644 Standard (Clean Rooms): Ensures that the air where cells are processed is 99.9% pure, eliminating particles.
- ISO 13022 Standard: Guarantees that cells are viable and functional. Dead or "old" cells have no therapeutic effect.
The quality of the biologic is as important as the therapy itself.
Frequently Asked Questions: Fibrosis and Regeneration
Can I stop using oxygen if I undergo treatment?
The initial goal is not to "remove oxygen," but to improve saturation and exercise tolerance. Some patients manage to reduce the necessary flow rate, but this varies depending on accumulated damage.
Does it work for post-COVID Fibrosis?
Yes. Post-infectious pulmonary sequelae share inflammatory mechanisms similar to idiopathic fibrosis. Cell therapy has proven to be very effective in reducing residual inflammation in these cases.
How do I know if I am a candidate?
A review of your recent chest CT scan and spirometry is required. We do not treat patients with active respiratory infections (pneumonia). A medical assessment is indispensable.
References
- Wan R, Liu Y, Yan J, Lin J. (2025). Cell therapy: A beacon of hope in the battle against pulmonary fibrosis. FASEB J. 39(2):e70356.
- Glassberg, M. K., et al. (2017). Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Clinical Trial. Chest.
A Breath of Scientific Hope
If you or a family member are facing a Pulmonary Fibrosis diagnosis, know that science is advancing to offer more than palliative care. At Regencord, we combine safe biotechnology with human management.
Schedule a medical assessment today to evaluate if our pulmonary regeneration protocol is right for your case.
